Impact of rs1344706 or rs1006737 polymorphisms on cognition in patients with severe mental disorders: A systematic review and meta-analysis.

OBJECTIVES

This systematic review and meta-analysis focussed on insights into the relationship between -rs1006737 and -rs1344706 polymorphisms and cognitive performance in schizophrenia (SCZ) spectrum and bipolar disorder (BD) and provide some contributions for clinical practice.

METHODS

We searched the websites databases (PubMED, PsycINFO, Web of Science, EMBASE and Cochrane Library) using eligibility and exclusion criteria to capture all potential studies, based on PICO model and according to the PRISMA.

RESULTS

Eight articles were included in this systematic review (five referring to -rs1006737 and three related to -rs1344706 polymorphisms), with a total of 5759 participants (1751 SCZ patients, 348 BD patients, 3626 controls and 34 first-degree relatives). The results demonstrated that the pooled effect of -rs1006737 (risk difference RD = 0.08; 95% CI 0.02-0.15) was associated with altered cognitive function in patients with severe mental disorders, but not Z-rs1344706 polymorphism (RD = 0.19; 95% CI 0.09-0.48.

CONCLUSION

The present meta-analysis provides evidence regarding slight association between -rs1006737 polymorphisms and cognitive performance in severe mental disorders, indicating that cognitive impairment in severe mental disorders associated with the rs1006737 risk variants could only be expressed when interacting with environmental exposures. This study is registered with PROSPERO, number CRD42021246726.